All In Biotech

Drug Trial Radar · NCT06049095

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

A Sequential, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally of Intravenously to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Male and Female Participants 18 to 55 Years of Age

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Oct 17, 2023

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Latigo BiotherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants

Conditions

  • Healthy

Interventions

  • LTG-001Drug

    Oral doses

  • PlaceboDrug

    Oral doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of single and multiple ascending oral doses, relative bioavailability and food effect of LTG-001 in healthy subjectsTime frame: Up to 10 days of dosing
  2. Absolute Bioavailability of LTG-001 Following Oral and Intravenous AdministrationTime frame: from admission to completion in the study (35 days)
  3. Safety and Tolerability of Intravenous LTG-001Time frame: From first intravenous dose through end of study (up to 14 days following intravenous dosing)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Unit

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.